Primärquellen-Eintrag

EntscheidungsrelevantComplete Response Letter

AbbVie Inc. · Complete Response Letter (BLA 761459)

FDA hat einen Complete Response Letter für BLA 761459 mit Datum 2026-04-22 ausgestellt.

Kernfakten

Eingereicht
22. Apr. 2026, 00:00
Ereignis
Complete Response Letter
Richtung
Negativ
Unternehmen
ABBVAbbVie
Quelle
openFDA
Belegstatus
Belegt

Auszug aus der Quelle

nN U.S. FOOD & DRUG ADMINISTRATION BLA 761459 COMPLETE RESPONSE AbbVie Inc. Attention: Felipe Martins Associate Director, Regulatory Affairs 2525 Dupont Drive Irvine, CA 92612 Dear Felipe Martins: Please refer to your biologics license application (BLA) dated and received April 22, 2025, and your amendments, submitted under an for AGN-151586 for injection. We also acknowledge receipt of your amendment dated April 17, 2026, which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter. We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons f

openFDA